Merck Wants Genentech's Cancer Drug Patent Invalidated
Merck & Co. Inc. filed a suit in California federal court on Thursday seeking a ruling that a key Genentech Inc. patent covering biotechnology used to make cancer drugs is invalid...To view the full article, register now.
Already a subscriber? Click here to view full article